Section Arrow
Quote
SRPT.NASDAQ
- Sarepta Therapeutics
Quotes are at least 15-min delayed:2026/04/21 23:24 EDT
Regular Hours
Last
 20.68
-0.74 (-3.45%)
Day High 
21.56 
Prev. Close
21.42 
1-M High
23.85 
Volume 
3.09M 
Bid
20.7
Ask
20.87
Day Low
20.515 
Open
21.5 
1-M Low
16.67 
Market Cap 
2.25B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 21.82 
20-SMA 21.47 
50-SMA 19.06 
52-W High 64.8 
52-W Low 10.415 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-7.13/1.95
Enterprise Value
3.28B
Balance Sheet
Book Value Per Share
10.86
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
2.20B
Operating Revenue Per Share
10.52
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1968-0.0651-24.86%-- 
XRTXXORTX Therapeutics Inc.2.69+0.44+19.56%-- 
TOVXTheriva Biologics Inc0.3387-0.0713-17.39%0.09PE
GERNGeron Corp1.5-0.06-3.85%-- 
SPRCSciSparc Ltd.5.99+1.76+41.61%0PE
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.